Subscribe To
GERN / Geron's Data Allows Development Of Several Catalysts
GERN News
By Seeking Alpha
October 23, 2023
Geron Corporation Stock: Another Buying Opportunity
Geron Corporation stock has nearly halved since July, leading to concerns about whether the price will go back up. Geron's telomerase inhibitor imetel more_horizontal
By Invezz
September 12, 2023
Buy biotech stock Geron for a 70% return in 12 months: Goldman Sachs
Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs anal more_horizontal
By InvestorPlace
September 12, 2023
Why Is Geron (GERN) Stock Up Today?
Geron (NASDAQ: GERN ) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares. Goldman Sachs analyst Corinne Jenki more_horizontal
By Business Wire
June 7, 2023
Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal
By Zacks Investment Research
June 1, 2023
Geron (GERN) Just Flashed Golden Cross Signal: Do You Buy?
Geron Corporation (GERN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GERN's 50 more_horizontal
By Business Wire
May 11, 2023
Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMe
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that five abs more_horizontal
By The Motley Fool
April 20, 2023
Why Shares of Geron Are Up 30% This Week
Geron's imetelstat has shown promise to treat a rare blood disorder. The drug could have wide oncology applications. more_horizontal
By Business Wire
April 12, 2023
Geron to Present at Upcoming Investor Conferences in April
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. more_horizontal